Radical Numerics Raises $50M Seed Round to Build AI for Biology

Radical Numerics is a San Francisco-based AI research lab building general biological intelligence and has emerged from stealth with a $50M seed round led by Emergence Capital, with participation from Obvious Ventures, Triatomic Capital, Factory, and First Spark Ventures.

The company was founded by Eric Nguyen (CEO), Michael Poli (Chief AI Scientist), Stefano Massaroli (President), and Armin W Thomas (CTO), a team known for its work on Evo and Evo 2, projects that helped establish generative genomics as an emerging category within AI-driven biological research.

Radical Numerics is building systems designed to read, write, and design across biological systems spanning DNA, RNA, proteins, and regulatory networks. The company's broader goal is to create what it calls general biological intelligence, bringing biological foundation models closer to real-world applications in healthcare, diagnostics, scientific discovery, and biodefense.

The funding arrives as venture capital increasingly shifts toward AI platforms capable of generating measurable outcomes in science, medicine, and national security rather than purely digital workflows.

---

Funding Snapshot

Company: Radical Numerics
Website: radicalnumerics.ai
Headquarters: San Francisco, California
Funding Round: $50M Seed
Lead Investor: Emergence Capital
Participating Investors: Obvious Ventures, Triatomic Capital, Factory, First Spark Ventures
Founders: Eric Nguyen (CEO), Michael Poli (Chief AI Scientist), Stefano Massaroli (President), Armin W Thomas (CTO)
Sector: AI for Biology, Computational Biology, Generative Genomics, Biodefense

---

What Happened

The AI industry has spent the last few years teaching machines to write essays, generate images, and produce software code. Radical Numerics is aiming at a much older language: biology.

The company announced a $50M seed round through its official launch, led by Emergence Capital and supported by Obvious Ventures, Triatomic Capital, Factory, and First Spark Ventures. For a company emerging from stealth, the size of the round immediately places Radical Numerics among the most closely watched startups in the rapidly expanding AI-for-biology sector.

The founding team brings unusually deep credentials to the table. Eric Nguyen, Michael Poli, Stefano Massaroli, and Armin W Thomas previously worked on Evo and Evo 2, generative genomics projects that demonstrated how large-scale AI models could move beyond analyzing DNA and begin designing biological sequences. Those efforts laid much of the foundation for what Radical Numerics is pursuing today.

Many startups arrive with ambitious narratives and fundraising momentum, but Radical Numerics arrived with a research track record that investors already recognized. The company's mission is straightforward to describe and extraordinarily difficult to execute: build AI systems capable of understanding biology as an interconnected system rather than a collection of isolated biological tasks.

---

Why This Matters

The most consequential AI opportunities are increasingly moving away from digital convenience and toward physical outcomes. Generating marketing copy is useful. Understanding cancer pathways, identifying disease mechanisms, detecting pathogens, and accelerating biological discovery is consequential.

Radical Numerics sits directly inside that transition. The company says its systems are designed to operate across DNA, RNA, proteins, and broader biological structures. That approach reflects a growing belief among researchers that biology cannot be effectively modeled through disconnected datasets and narrow-purpose algorithms.

Living systems do not operate in silos. Genes influence proteins, proteins influence cellular behavior, and cellular behavior influences disease progression. Every layer affects the next. For decades, biotechnology has often approached those relationships through fragmented tools.

Radical Numerics is betting that biological foundation models can uncover patterns traditional approaches struggle to identify. The company has already discussed applications involving cancer detection, drug target identification, pathogen characterization, and biodefense. Those are some of the largest healthcare and national security challenges facing governments, researchers, and industry today.

---

Market Context

The funding environment around AI has become increasingly selective. Investors are no longer impressed simply because a company places AI on a pitch deck. Capital is flowing toward teams with technical depth, proprietary research, and defensible scientific advantages.

Radical Numerics appears to fit that profile. Its emergence comes amid growing interest in computational biology, genomic foundation models, AI-driven drug discovery, and biological design platforms. Across biotech and pharmaceutical research, organizations are searching for ways to shorten development timelines, improve discovery rates, and better understand biological complexity.

Biology remains one of the most difficult domains for machine intelligence. Unlike software, biological systems rarely produce clean, deterministic outcomes. Every breakthrough arrives with uncertainty, edge cases, and variables that cannot always be isolated.

That complexity creates opportunity, but it also creates substantial barriers to entry. Building large-scale biological AI systems requires expertise across machine learning, genomics, systems engineering, and scientific research. Few teams possess all 4 capabilities at a world-class level.

---

Competitive Landscape

The broader AI-for-biology ecosystem has become one of the most strategically important segments in technology. Companies across healthcare AI, computational biology, synthetic biology, and drug discovery are racing to build models capable of understanding biological systems with the same fluency that large language models understand human language.

Radical Numerics enters that market with a background deeply connected to generative genomics and long-context biological modeling. The company is previewing Omnii, its next-generation genomic language model designed to reason across biological systems.

According to company materials, Omnii is being developed to support applications spanning human health, diagnostics, biological discovery, and biodefense. Infrastructure is becoming an equally important competitive differentiator. Training advanced biological models requires enormous computational resources, and Radical Numerics has disclosed plans involving NVIDIA Blackwell-powered infrastructure.

The AI race is no longer only about algorithms. It is also about who can secure the infrastructure required to train increasingly sophisticated models.

---

What This Signals

The Radical Numerics funding round signals something larger than the emergence of a single startup. It reflects a growing convergence between AI, biology, healthcare, and national security.

For years, AI investment largely centered around enterprise software productivity. Today, capital is moving toward scientific discovery, diagnostics, drug development, biosurveillance, and biosecurity. That shift represents a natural evolution of the market.

Once foundational AI capabilities become established, attention moves toward sectors where intelligence can generate measurable real-world outcomes. The companies attracting major funding increasingly share common characteristics: deep technical teams, research-first cultures, long-term scientific missions, and massive addressable markets.

Radical Numerics checks all 4 boxes.

---

The Bigger Industry Shift

Every major technology cycle eventually moves from information toward infrastructure. The internet digitized information. Cloud computing digitized infrastructure. Modern AI is beginning to digitize scientific discovery itself.

That trend is becoming increasingly visible across healthcare, pharmaceuticals, defense, and advanced research organizations. The emergence of companies like Radical Numerics suggests investors believe the next generation of AI value creation may come from understanding the physical world rather than simply organizing digital content.

Biology remains one of humanity's most complex systems, but it is also one of its most valuable. The companies capable of turning biological complexity into computational understanding could influence healthcare, diagnostics, therapeutics, biodefense, and scientific discovery for decades.

Whether Radical Numerics ultimately succeeds remains an open question. The size of the opportunity is not.

---